Biogen (BIIB)
(Delayed Data from NSDQ)
$224.94 USD
+4.87 (2.21%)
Updated May 31, 2024 04:00 PM ET
After-Market: $224.85 -0.09 (-0.04%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth C Momentum B VGM
Brokerage Reports
0 items in cart
Biogen Inc. [BIIB]
Reports for Purchase
Showing records 301 - 320 ( 803 total )
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Monthly Institutional Prescription Sales -- June 2021
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Weekly Neurology Prescription Sales Tracker -- Week Ending 7/9/21
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Weekly Neurology Prescription Sales Tracker -- Week Ending
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Weekly Neurology Prescription Sales Tracker
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for BIIB.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for BIIB.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
With Gosuranemab, the Fate of N-terminal Tau Antibodies Could Be Sealed
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Going Over The WATERFALL Results - We Still Think There''s A Path Forward
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Weekly Neurology Prescription Sales Tracker -- Week Ending 6/4/21
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for BIIB.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
The Pubmed Times - Interplay of Astrocytic APOE4 and Microglial TREM2 in Tau-Mediated Neurodegeneration
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
All''s Well That Ends Well for Aducanumab; PT to $452
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
If You Build It, Will They Come? We''re Still Skeptical
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
So, This Is Actually Happening... Aduhelm (Aducanumab) Approved
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Neurology Prescription Sales Tracker - Week Ending 5/28/21
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L